Tsugiyasu Kanda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tsugiyasu Kanda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Isao Kobayashi
Department of Laboratory Medicine, Gunma University School of Medicine
5 shared publicationsKen-Ichi Sekiguchi
Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371, Japan
2 shared publicationsRyozo Nagai
Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371, Japan
2 shared publicationsYukihiro Seta
Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371, Japan
2 shared publicationsBruce M. McManus
Department of Pathology and Laboratory Medicine, University of British Columbia, St. Paul's Hospital, 2211 Westbrook Mall, Vancouver, BC, V6T2B5, Canada
1 shared publicationDeCheng Yang
Department of Pathology and Laboratory Medicine, University of British Columbia, St. Paul's Hospital, 2211 Westbrook Mall, Vancouver, BC, V6T2B5, Canada
1 shared publication
Latest Publications
- 1 January 2001
- Published by International Heart Journal (Japanese Heart Journal) in Japanese Heart Journal
- Vol. 42 (3) , 287-294
Evaluation of Signal-Averaged Electrocardiography for Clinical Diagnosis in Arrhythmogenic Right Ventricular Dysplasia.
Arrhythmogenic right ventricular dysplasia (ARVD) is a heart muscle disorder of unknown etiology that is characterized pathologically by fibrofatty replacement of the right ventricular myocardium. We investigated the relationship between the electrocardiogram (ECG) appearances and signal-averaged ECG (SAECG) in 7 cases with ARVD, and evaluated the usefulness of SAECG as a screening test to detect patients with ARVD. Compared with the conventional 12-lead ECG, the SAECG detects abnormalities at a higher rate in ARVD patients (57% versus 86%). SAECG was more sensitive as a screening test to detect patients with ARVD than 12-lead ECG.
- 1 January 2001
- Published by International Heart Journal (Japanese Heart Journal) in Japanese Heart Journal
- Vol. 42 (3) , 287-294
Evaluation of Signal-Averaged Electrocardiography for Clinical Diagnosis in Arrhythmogenic Right Ventricular Dysplasia.
Arrhythmogenic right ventricular dysplasia (ARVD) is a heart muscle disorder of unknown etiology that is characterized pathologically by fibrofatty replacement of the right ventricular myocardium. We investigated the relationship between the electrocardiogram (ECG) appearances and signal-averaged ECG (SAECG) in 7 cases with ARVD, and evaluated the usefulness of SAECG as a screening test to detect patients with ARVD. Compared with the conventional 12-lead ECG, the SAECG detects abnormalities at a higher rate in ARVD patients (57% versus 86%). SAECG was more sensitive as a screening test to detect patients with ARVD than 12-lead ECG.
- 31 December 2000
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 32 (12) , 2163-2171
Effect of Interleukin-18 on Viral Myocarditis: Enhancement of Interferon- γ and Natural Killer Cell Activity
- 31 December 2000
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 32 (12) , 2163-2171
Effect of Interleukin-18 on Viral Myocarditis: Enhancement of Interferon- γ and Natural Killer Cell Activity
- 1 January 2000
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 47 (4) , 407-416
Antipituitary Antibodies as Pathogenetic Factors in Patients with Pituitary Disorders.
Our previous reports showed detection of antipituitary antibodies (APA) by immunoblot analysis and enzyme linked immunosorbent assay (ELISA) by using rat pituitary tissue as antigen in patients with certain endocrine disorders. In the present report, we evaluated APA by using our immunoblot and ELISA technique in 76 patients with various pituitary disorders. The prevalence of a 22kDa band of APA detected by immunoblot was found to be significantly higher (P<0.01) in patients with pituitary disorders (20 of 76, 26% than in the controls (3 of 209, 1%). APA levels detected by ELISA were significantly higher in patients with GH deficiency, isolated ACTH deficiency, acromegaly, and idiopathic panhypopituitarism compared with control (mean±SD; 2.40±2.66, 2.36±1.87), 2.09±1.87, 3.10±1.96 versus 1.42±0.64 (C.I.) P<0.05, respectively). APA levels detected by ELISA in 7 patients with GH deficiency showed a statistically significant decrease (p<0.05) after administration of GH replacement therapy. APA detection by immunoblot is useful in examining as pathogenesis, while ELISA may be useful as an objective index of pathological state in patients with autoimmune-related pituitary disorders.
- 1 January 2000
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 47 (4) , 407-416
Antipituitary Antibodies as Pathogenetic Factors in Patients with Pituitary Disorders.
Our previous reports showed detection of antipituitary antibodies (APA) by immunoblot analysis and enzyme linked immunosorbent assay (ELISA) by using rat pituitary tissue as antigen in patients with certain endocrine disorders. In the present report, we evaluated APA by using our immunoblot and ELISA technique in 76 patients with various pituitary disorders. The prevalence of a 22kDa band of APA detected by immunoblot was found to be significantly higher (P<0.01) in patients with pituitary disorders (20 of 76, 26% than in the controls (3 of 209, 1%). APA levels detected by ELISA were significantly higher in patients with GH deficiency, isolated ACTH deficiency, acromegaly, and idiopathic panhypopituitarism compared with control (mean±SD; 2.40±2.66, 2.36±1.87), 2.09±1.87, 3.10±1.96 versus 1.42±0.64 (C.I.) P<0.05, respectively). APA levels detected by ELISA in 7 patients with GH deficiency showed a statistically significant decrease (p<0.05) after administration of GH replacement therapy. APA detection by immunoblot is useful in examining as pathogenesis, while ELISA may be useful as an objective index of pathological state in patients with autoimmune-related pituitary disorders.
- 1 January 2000
- Published by International Heart Journal (Japanese Heart Journal) in Japanese Heart Journal
- Vol. 41 (1) , 79-85
Therapy with the Nonpeptide Endothelin Receptor Antagonist 97-139 in a Murine Model of Congestive Heart Failure. Reduction of Cardiac Mass and Myofiber Hypertrophy.
Endothelin-1 (ET-1) is a potent vasoconstrictor. This peptide exerts numerous effects on the heart, including regulation of cardiomyocyte growth during hypertrophy. The effects of the structurally novel, nonpeptide, ET-1-selective, competitive antagonist (ETA) 97-139 were investigated in mice with congestive heart failure (CHF) and myocardial hypertrophy. Morphological and microscopical analyses were conducted on day 56 after viral inoculation following 28 day treatment with 99-139. Eight week-old DBA2 mice were intraperitoneally inoculated with encephalomyocarditis virus at a dose of 500 pfu/mouse. The 30 mice were divided into two groups--an ETA treated group and an untreated group. Heart weight (HW) in the infected group was significantly (p < 0.05) increased compared to that in the uninfected group. HW and the HW/body weight (BW) ratio were significantly (p < 0.05) reduced in the ETA treated group compared with the untreated group (HW; 127.7 +/- 6.2 mg vs 144.3 +/- 4.2 mg, HW/BW; 4.9 +/- 0.9 x 10(-3) vs 5.4 +/- 0.5 x 10(-3)). Myofiber diameter in the ETA treated group was significantly reduced compared with the untreated group (12.1 +/- 1.5 microm vs 14.3 +/- 1.9 microm). These results suggest the ET-1 receptor antagonist 97-139 has an effect on the reduction of cardiac mass and myofiber hypertrophy, and that 97-139 may be a useful agent for CHF due to viral myocarditis.
- 1 January 2000
- Published by International Heart Journal (Japanese Heart Journal) in Japanese Heart Journal
- Vol. 41 (1) , 79-85
Therapy with the Nonpeptide Endothelin Receptor Antagonist 97-139 in a Murine Model of Congestive Heart Failure. Reduction of Cardiac Mass and Myofiber Hypertrophy.
Endothelin-1 (ET-1) is a potent vasoconstrictor. This peptide exerts numerous effects on the heart, including regulation of cardiomyocyte growth during hypertrophy. The effects of the structurally novel, nonpeptide, ET-1-selective, competitive antagonist (ETA) 97-139 were investigated in mice with congestive heart failure (CHF) and myocardial hypertrophy. Morphological and microscopical analyses were conducted on day 56 after viral inoculation following 28 day treatment with 99-139. Eight week-old DBA2 mice were intraperitoneally inoculated with encephalomyocarditis virus at a dose of 500 pfu/mouse. The 30 mice were divided into two groups--an ETA treated group and an untreated group. Heart weight (HW) in the infected group was significantly (p < 0.05) increased compared to that in the uninfected group. HW and the HW/body weight (BW) ratio were significantly (p < 0.05) reduced in the ETA treated group compared with the untreated group (HW; 127.7 +/- 6.2 mg vs 144.3 +/- 4.2 mg, HW/BW; 4.9 +/- 0.9 x 10(-3) vs 5.4 +/- 0.5 x 10(-3)). Myofiber diameter in the ETA treated group was significantly reduced compared with the untreated group (12.1 +/- 1.5 microm vs 14.3 +/- 1.9 microm). These results suggest the ET-1 receptor antagonist 97-139 has an effect on the reduction of cardiac mass and myofiber hypertrophy, and that 97-139 may be a useful agent for CHF due to viral myocarditis.
- 1 July 1995
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 26 (1) , 61-65
Comparative Effects of Losartan, Captopril, and Enalapril on Murine Acute Myocarditis Due to Encephalomyocarditis Virus
Losartan, a recently developed nonpeptide angiotensin II (AII) receptor antagonist, was orally administered for 14 days to mice with viral myocarditis, beginning 7 days after encephalomyocarditis virus inoculation. The angiotensin-converting enzyme inhibitors (ACEI) captopril and enalapril were also administered in the same manner to compare the therapeutic effects of these three drugs on the degree of myocarditis, acute heart failure, and left ventricular (LV) hypertrophy. Heart weight and the heart weight/body weight ratio were reduced by losartan (60 mg/kg/day) and captopril (7.5 mg/ kg/day), but not by enalapril (1 mg/kg/day). LV wall thickness and cavity dimension were decreased in the losartan and captopril groups. Captopril reduced both myocardial necrosis and inflammation, whereas enalapril reduced myocardial necrosis but not inflammation. However, none of the studied losartan doses (1.2, 12, 60 mg/ kg/day) influenced myocardial necrosis and inflammation resulting from viral infection. Thus, specific blockade of AII is beneficial in congestive heart failure (CHF) and LV hypertrophy but is not effective in viral-evoked inflammation and injury.
- 1 July 1995
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 26 (1) , 61-65
Comparative Effects of Losartan, Captopril, and Enalapril on Murine Acute Myocarditis Due to Encephalomyocarditis Virus
Losartan, a recently developed nonpeptide angiotensin II (AII) receptor antagonist, was orally administered for 14 days to mice with viral myocarditis, beginning 7 days after encephalomyocarditis virus inoculation. The angiotensin-converting enzyme inhibitors (ACEI) captopril and enalapril were also administered in the same manner to compare the therapeutic effects of these three drugs on the degree of myocarditis, acute heart failure, and left ventricular (LV) hypertrophy. Heart weight and the heart weight/body weight ratio were reduced by losartan (60 mg/kg/day) and captopril (7.5 mg/ kg/day), but not by enalapril (1 mg/kg/day). LV wall thickness and cavity dimension were decreased in the losartan and captopril groups. Captopril reduced both myocardial necrosis and inflammation, whereas enalapril reduced myocardial necrosis but not inflammation. However, none of the studied losartan doses (1.2, 12, 60 mg/ kg/day) influenced myocardial necrosis and inflammation resulting from viral infection. Thus, specific blockade of AII is beneficial in congestive heart failure (CHF) and LV hypertrophy but is not effective in viral-evoked inflammation and injury.